Aspirin may help older people to live well for longer by delaying the onset of illnesses. In fact, previous studies have shown that low dose aspirin:
- Reduces the risk of heart attack, stroke and vascular events in middle aged people
- May help to prevent cognitive decline and forms of cancer such as bowel cancer
However, aspirin is known to have adverse-effects, such as bleeding, that may offset its benefits. Before doctors can know for sure if aspirin is helpful in prolonging a healthy life in older people, the benefits must be weighed against the risks.
The ASPREE study, for the first time, will determine whether the potential benefits of aspirin outweigh the risks for people over age 65.
The Trial -
- ASPREE is a randomized, double-blind placebo controlled study
- It involves both males and females, 65 years and older
- Participants are randomly assigned (or randomized), like the flip of a coin, to take either a low-dose aspirin tablet (100mg) or a placebo tablet (dummy pill) for a period of 5 years
- The study will recruit 19,000 healthy participants through regional centers (both in urban and rural locations throughout Australia and the United States)
- Annual follow-up visits will involve a number of health, clinical and other measurements
Any abnormalities will be reported to the participant’s doctor for further assessment
*ASPREE has completed enrollment of Caucasian participants.*
To find an ASPREE clinic near you, please click here.